What is Cerevance?
Cerevance is a Boston, MA-based private company dedicated to advancing the understanding and treatment of brain diseases. Leveraging its proprietary NETSseq technology, Cerevance analyzes cell-type-specific transcriptional and epigenetic profiles in human brain tissue, spanning nine decades of age. This approach aims to reveal critical biological insights that can inform the development of new therapeutic strategies for neurodegenerative and other brain-related conditions.
How much funding has Cerevance raised?
Cerevance has raised a total of $184.5M across 3 funding rounds:
Series A
$21.5M
Series B
$116M
Other Financing Round
$47M
Series A (2016): $21.5M with participation from Lightstone Ventures launched and Takeda Pharmaceutical Company
Series B (2023): $116M led by Dementia Discovery Fund, UPMC, GV, Dolby Family Ventures, Lightstone Ventures, Takeda, Bill Gates, Casdin Capital, and Foresite Capital
Other Financing Round (2024): $47M supported by Agent Capital
Key Investors in Cerevance
Agent Capital
Agent Capital is a healthcare venture capital firm that invests in novel therapeutics and treatments aimed at addressing unmet patient needs. The firm collaborates with scientists, entrepreneurs, and investors to foster the development of innovative healthcare solutions across various stages of development. Their investment focus includes key areas such as rare diseases, oncology, neurology, and immunology. Agent Capital is dedicated to guiding biotech companies towards significant milestones and successful exits.
Dementia Discovery Fund
The Dementia Discovery Fund (DDF) is a venture capital fund focused on investing in companies developing treatments for dementia. It brings together government, industry, and philanthropic organizations to accelerate the discovery and development of new therapies for Alzheimer's and other dementias.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors. The company focuses on enterprise solutions, life sciences, consumer products, and frontier technology innovations. GV operates globally with presence across North America, Europe, Asia, and South America, providing financial backing to promising startups and growth-stage businesses. The firm maintains a diverse investment portfolio spanning technology, healthcare, and various other industries.
What's next for Cerevance?
With its recent major enterprise-level funding, Cerevance is poised to accelerate its research and development initiatives. The company's focus on detailed cellular and molecular analysis of the aging human brain positions it to make significant contributions to the field of neuroscience. Future endeavors will likely involve further validation of its findings, potential therapeutic target identification, and strategic partnerships to translate its discoveries into clinical applications. The substantial backing suggests confidence from investors in Cerevance's innovative approach to tackling complex neurological disorders.
See full Cerevance company page
